Replay available

MDB Capital Holdings (NASDAQ:MDBH) Q3 2026 Earnings Call

MDB Capital Holdings (NASDAQ:MDBH) Q3 2026 earnings call, held 2026-11-17. Watch the replay and read the transcript on 6ix.

Tue, November 17, 2026 at 4:30 PMendedReplay
MDB Capital Holdings (NASDAQ:MDBH) Q3 2026 Earnings Call
Company
MDB Capital Holdings, LLC (NASDAQ:MDBH)
Period
Q3 2026 earnings call
Date
Tue, Nov 17, 2026, 4:30 PM ET
Replay
Watch the replay on this page · 47 min
Results news release
MDB Capital Holdings Provides Third Quarter 2026 Update · Tue, Nov 17, 2026

On 6ix: 6ix.com/event/mdb-capital-holdings-llc-mdbh-q3-2026-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Welcome everyone to the MDB Capital Holdings third quarter 2026 update webinar. Thank you for joining us today. At this time, all participants are in listen-only mode. Before we begin the formal presentation, I'd like to remind everyone of several important things. Today's webinar is being recorded. A question and answer session will follow the formal presentation. So if you have questions during the presentation, you can type them into the Q&A chat to be answered during the Q&A session. Questions can only be seen by the moderator. Please remember that statements made on this webinar may contain provisions, estimates, or other information that might be considered forward-looking.

0:49 While these forward-looking statements represent our current judgment on what the future holds, They are subject to risk and uncertainties that could cause actual results to differ materially. You're cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Also, please be aware that we are not obligating ourselves to revise or publicly release results or any revision to these forward-looking statements, in light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our predictions.

1:35 You should also review our most recent Form 10Q for a more complete discussion of these factors and other risks, particularly under the heading of risk factors. A press release detailing these results which crossed the wire this afternoon is available in the investor relations section of our website mdb.com. A replay of this call will also be provided later on on mdb.com. Your host today is Chris Marlett, Chief Executive Officer and Co-Founder of MDB Capital Holdings. He'll be joined later by George Brandon, MDB President and Head of Community Development. Chris Marlett

2:49 So, I'm going to be decidedly upbeat because I really believe that what we set out to do when we started MDB and took it public was to generate big ideas. And, you know, our whole history has been based on creating new enterprises and giving these big ideas access to public liquidity. Albeit the markets have not been super hospitable to small companies, we've, you know, we've Christopher Marlett, Jeremy William James and our IP law firm, which we're very proud of.

3:53 We created this structure in the LLC so that we could distribute out assets. And that's exactly what we still intend to do is distribute these assets as soon as these companies hit an inflection point. And we think that some of these companies are very near an inflection point and why we are hopeful to be distributing out these assets very soon. We've executed on those ideas. We have not executed on launching more companies purely because of the backdrop of the current market. So when you look at, as we say, constrained access to capital and depressed valuations, we were hoping to launch two to three or four big ideas a year, which has just not been feasible in this market environment. But with the companies we have launched, we're very proud of them, and those companies have have executed on their mission to get to commercialization and close to a big inflection point.

4:59 So our road ahead right now with the market backdrop is to really make sure that the four key assets we have get to a value inflection point. And as we've talked about historically, it's public ventures, our clearing platform, patent vests, our disruptive new age IP law firm, Exozymes, which is, we believe, the leader in cell-free synthetic biology, which we think is going to be a huge market, and Pollux, folks that we have built a company with before that disrupted diabetes, and we believe this next drug or platform will disrupt diabetes again. So our core objective with all these assets has been to bring them to a value inflection point, and we're putting most of our efforts in helping those companies to get there at this time. We really need to see these companies perform and we're very excited about where they sit today and their ability to impact the markets that they're going to be serving.

6:04 We are going to be leaning up.

6:07 We're not blind to the market environment so we need to run a much leaner shop and we'll be cutting expenses while we're also liberating ourselves of current cash op-ex by funding and partnering public ventures in Patavest going forward. We believe significant value has been built and our teams have done magnificent work. They really have executed on standing up these companies and getting them close to commercialization. So our job is really to help each one of these companies get to that value inflection point as soon as humanly possible. So going to all four of the various opportunities, talk about why we did it, what we've accomplished, and what we see as the road ahead.

7:00 And so Public Ventures was a super simple concept. All of these companies that finance young micro-cap or small-cap companies had been challenged in the fact that clearing firms really didn't want to support support these type of firms anymore. We saw there was a huge opportunity to serve this marketplace. Obviously, most of investor capital has been going upmarket into very large companies. And now the market has largely been dominated by these companies. A lot of them, they're serving the AI marketplace. And, you know, the small companies have just been sort of forgotten for the most part. And We don't think that's sustainable. We think ultimately money will rotate back into this asset class, and we've always believed that you need to have a purpose-built current firm to serve that marketplace. We feel the exact same today as we did when we started it, but we've actually executed on getting it stood up. We also see that digital is going to become a very big part of it, whether that's tokenization, or crypto related assets. We do believe that investors are looking for different ways to invest in these companies and it's also a global it's a globalization situation. We have so many foreigners investing in the U.S.

8:33 capital markets today and increasingly looking for easier ways to do that whether that's through tokenized securities or and other platforms that enable, you know, a lot less friction investing in these kind of companies. We have the ability to do that and serve the, let's call it the micro caps or small cap marketplace. We don't think it's easy to copy. We think that our intellectual capital we have in this marketplace is significant. You know, we've been doing this for 30 years in this marketplace. And in fact, we have, you know, tremendous, you know, experience in doing this that nobody else has really, you know, there's very few other firms that have as much experience in this sector as we do. And getting a clearing license takes years to earn and actually get operational. And our firm's done it very cost effectively and very efficiently.

9:30 So, you know, we began this, you know, sort of I would say almost five-year journey to actually get this thing set up to where we could start clearing offerings and for those of you that have used MDB Direct and actually participate in the offerings, you see it works great. We built a great, you know, solid technical platform but now it's time for it to expand its capabilities and there are many ways that clearing firms make money, whether it's stock loan, margin and more active trading. Most of our accounts are not, you know, big time active traders and so we are in the discussions with numerous folks that are looking to have a clearing platform and utilize the strength of what we've built and our knowledge in this marketplace as well as taking advantage of our trained team in Latin America where we can operate not only with higher quality and those of you that have had a chance to deal with our operations team, you know that we have a very professional team that's doing a great job and we can do that in a very cost-efficient way. It's very hard to build a clearing firm in New York City today.

10:47 Expensive rent, expensive people. It's not the place to build it. We think we've built something super valuable with Public Ventures and we couldn't be more proud of what we've done. So where it stands is that we really have something that is ready set for someone that has visions for building These big platforms. And we've seen recently some firms transact, where we've seen companies like Kalshi just go and buy a brokerage firm to be able to do something similar to this. What turns out, there's only approximately 100 clearing broker-dealers in the U.S. As we know, it's not easy to get, and so I think that now we're at sort of this inflection point where we need to partner with someone to really bring scale to it.

11:41 We've been in discussions with several highly qualified folks that understand how to scale putting operations. They see the value in what we've created and we hope to conclude a transaction that we think will help realize the value of public ventures going forward. So we really see this as the next evolution of how new enterprises will enter the market. Even though today it is not the asset class of choice, we believe that money will rotate back into the sector as small companies need access to capital. We see the public markets as being a great place for that.

12:26 Patents. We saw a distinctly huge opportunity. What we saw in the area of patent law when we were starting new companies Especially companies that needed to file 50 or 100 patents to put a moat around their technology platform was it was not only very costly to do, but it was very difficult to do because no law firms really married business intelligence with IP law. And so when Arizona opened the door to enable this to be run in a in a business-like way as opposed to thinking about IP as a legal process. We thought of it as a business process. We saw this as a huge opportunity, and the team led by Javier Chamorro has done a phenomenal job of standing up this law firm. And we've brought on several lawyers.

13:20 We've trained paralegals. We have an entire analyst team that provides that critical sort of associate layer and now, of course, with AI, it's going to be supercharging this effort. So, what happened in the middle of building this, the great news is we were building this to serve a $30 billion global market that we knew was not being served by law firms currently and AI just dramatically sped up the disruption and it's, you know, I don't think that IP law is going to look anything like it has for the last five years, it's going to be very, very different going forward. And what we see is the key part of it is integrated business strategy, IP strategy, R&D, and have that in a really unified and connected way. And I'm 100% confident no law firm has delivered upon that, and we are now ready to do that.

14:27 And so What he took was training these analysts and paralegals and lawyers to work in this unified process. Of course, organizing it under Arizona law. And our technology is, we took 30 defined processes that we were building historically in a digital place, but without AI. What happened with AI is it just supercharged the entire effort. And it dramatically lowered our technology development costs But we had all these defined processes that were put in place that enabled us to be super efficient. And now with AI, we are achieving things that have never been achieved before in the practice of IP law.

15:12 We can take something from an invention, put it into business context, IP context, develop claims that can be granted by the patent office. Examine those claims, and when we file it, we can literally demonstrate we can do this in one day. This would take months before to happen. It is the most disruptive thing I've ever seen. When we've got a company like Exozymes that needs to probably file a hundred patent applications a year, there's no way that that could have been done both cost-effectively and efficiently in any kind of way. We now have the ability to process 1,000 patent applications a year in a legally compliant manner.

15:59 And legally compliant is really the most key aspect of what we're talking about because you can't just put things into ChatGPT or Claude as an inventor or as a lawyer and effectively process that whole application to grant a patent in that way. And so... Thank you for having me. and I really do believe we have a real lead over other people and that it will not become easily replicated because we were built to do it this way from the very beginning.

16:59 And so where it stands, the tech stack is built, the team is trained and it's no longer just talk. We can demonstrate it. We can go to companies that are processing hundreds of patents a year and say we can absolutely do a better job than that big name law firm. and we can demonstrate it. To actually prove it, we've actually taken some of the patent applications that are public and examined them and showed them how bad the quality is that these other law firms are filing of their patents and how we can improve it. It really is disruptive. When we're sitting down with new potential clients, we can actually demonstrate it to them, which again is, I think, going to be very disruptive.

17:44 So we're going to complete a financing to scale up that marketing, bring in salespeople that can make it plainly obvious to the client that they need to transition their business to patent vest. And we think that a growing client base can get this to profitability fairly quickly on not a lot of capital. So we think we can create a lot of value. We think we can attract great lawyers because great lawyers will have to be on a platform like this. and we're super excited about it. We believe that the practice of law will never be the same and we're going to be a leader in this segment. So I really want to thank the team, the hard work that the team at PatVest has done to get us there. It's been, you know, a concentrated two and a half years of hard work to get there, but we're there and we're ready for scale and it's an exciting time.

18:39 And so exozymes, What did we see with exozymes? It was super simple. Everybody knew that synthetic biology was the future of being able to create natural products that synthetic chemistry could not create or could not be extracted from the natural products in any kind of economic way. And so there were companies like Ginkgo and others that went to multi-billion dollar valuations. Amaris, Zymogen, What they proved was that they couldn't scale in a cell-based environment, which is through fermentation. What we had seen from the scientists at UCLA when we spun it out was that taking a cell-free process with just enzymes, that this was promising it could be done. Well, in fact, the team has now proven it and has proven that the manufacturing process can scale.

19:39 and taking it beyond our first product and now creating a whole pipeline of products. So, you know, this has been a monumental accomplishment by the team at Expozymes. While the market has not yet recognized it yet, I can tell you being on the board, being there day to day, I can see that we have also with AI been able to and many, many more. Things that, you know, that we would start off thinking, well, maybe we can make it for $3,500 a kilo. We can make it for now under $1,000 a kilo.

20:41 That's really important when you're creating, you know, a nutritional supplement. People can't pay, you know, $5 a day to take a nutritional supplement. It's got to be effective, and it's also got to be cost effective as well. And now we've been able to achieve that. not only with NCT and we're now believing we can achieve it with other compounds as well that have great scientific validation that we believe could sell hundreds of millions if not billions of dollars of product going forward and could be some of the biggest nutritional supplements ever launched. So there's a whole host of numerous compounds in the pipeline and these nutraceutical companies and pharma companies need new compounds.

21:30 If you're a nutraceutical company and you're great at marketing nutritional supplements, you need something that's proprietary that nobody else has because you're not going to make any money selling vitamin D when there's 50 people selling vitamin D. You need new compounds that are proprietary and exosomes can deliver that. Pharma, as you can see, is getting desperate as they're facing patent cliffs and they're starting to buy companies for very large valuations that are very early in development. And so we are very confident that we can show them new compounds that have great scientific groundings underneath them or foundations underneath them that affect pathways that they know exist. And so we're super excited about our ability to sit down with them and actually gets your partnerships.

22:25 Those partnerships are critical to getting these compounds to market because we're in the business of discovery and manufacturing, not in the business of actually launching these products. So those partnerships will bring scale to those, and I think you'll see some announcements shortly of relationships that will start to show that these are going to be marketed by other companies. So we believe these compounds can create billions of dollars of value, potential market value for exosomes and the partners. And that's never really been possible in synthetic biology before, and you can never tell it from the stock price, but we do believe that it will get recognized.

23:10 It is real. Anybody that wants to go visit the company, bring the most brilliant scientist you want to the company to go see it in person, we encourage you to do it. This is an extraordinary opportunity that we're very proud of. And lastly is Pollux Bios. So Pollux, if you remember, we started the company with folks that we started prevention with that was a big success for us. A company that pioneered treatment of type 1 diabetes or helping delay or prevent type 1 diabetes through a drug that had, you know, People had a lot of questions about, but it actually got approved, it worked, and the company got bought for $2.9 billion.

23:58 And we worked with them to license a new drug that we're super excited about that will effectively, hopefully, enable people to regrow beta cells to make insulin again. So whether it's a type 1 diabetic or a type 2 diabetic, obviously the market is huge. It also fits really where major drug companies are looking for things. It's a small molecule, so it's a pill. It's not a biologic. It's very, very different than the road we had with prevention, which was a biologic, which was difficult to manufacture, and difficult to dose as well. And so that enables what we say is asymmetric upside, where if this pill works, The kind of return, you know, to our investors because of the promises and how it will fit with Big Pharma is really, you know, potentially very huge.

25:02 And so, as I said, we worked with them to license that drug from Mount Sinai and do a $19 million seed round. We are probably about two months behind on, you know, we were looking at sort of Thank you for joining us. and we have planned, we filed a registration statement confidentially. We do believe that the company would like to go public in the first half of next year and we're working toward that process now and we hope to see that the company is public as well as hitting the critical milestones of safety and potentially efficacy by showing that beta cells can be regrown.

26:05 So, as I said, the first milestone is safety, and we hope to be able to start to show that here very soon. And because this drug in preclinical studies is potentiated by GLP-1, it actually dramatically increases the effectiveness of it. We think it's a natural to be partnered with the pharma company's that are battling it out in the GLP-1 space. And we know that they need to have something that's unique and differentiated like this drug to give them, you know, a seat at the table in this new space that is turning into a, you know, potentially $100 billion market and growing over the next few years.

26:55 So, for the first nine months, we had fee income of about $4.2 million. It's up from last year. So that ameliorated our burn a bit this past year. And so we kept costs relatively the same. And now through spinning out and effectively funding PatentVest and Public Ventures separately, we can bring our cash utilization down significantly. And so right now we're working on those two financings and spinning those out and partnering those out, as I've discussed earlier, which dramatically extends our runway. We had about $8.3 million in operating cash. We had some other deposits for clearing and things like that that increased that cash position. But our goal is to reduce that operating spend so that we're not having to raise additional capital to extend our runway to get these things to a value and function point.

27:54 So, as the largest shareholder, I can tell you the last thing I want to see is dilution. And I want to make sure that we get these things to a value creating point and then distribute those, you know, that value out to the shareholders as soon as humanly possible. So, again, to reiterate, you know, the structure was set up to do that. We're not going back on that promise. You know, we want to deliver these assets out and I think that We expect to have distributions in 2027 of those assets to the shareholders. And we're right now reviewing that with the board about how to do that, when to do that.

28:41 But our goal is to deliver as much out to the shareholders in 2027 as possible. And we hope to have some important updates on that shortly. So While I'm decidedly upbeat and I'm very excited about what we've done in launching these four companies, we also have to manage risk. And the risk is we're still doing financings for companies like Exozymes, Pollax, and we can't control the markets around those. And so the timing of those transactions and financings are important. We're working hard on that. We're in the midst of of, you know, spending a lot of our time focused in that area. The science, you know, I think the science is now well-established at Exozymes, and I think we'll start, and the science is well-established at Pollux, but there's some critical milestones with both safety and efficacy for Pollux that we're going to see in the very short term that will impact dramatically the valuation of that company.

29:54 Concentration in these assets can be good or bad, but I think that we have four assets. If any one of them work out great, we believe that it could create multiples of our current stock price. If you think about Exozymes or Pollux or any of these going to significant valuations, it has a big levering aspect on our stock being that we have just under 11 million shares outstanding. So we're still very hopeful that at least one of them works out. If one of them works out, it could be great. If all of them work out, it could be phenomenal. The markets for small public companies, I don't have to keep reiterating that. You guys know what that's like.

30:45 We've seen a company like Buda that we don't have a huge equity interest in. But we love the company, and they've done nothing but perform. They have crushed it. They just announced earnings this week. Their revenues were up 60%. Earnings were up great. I mean, we are completely convinced that Fresh Juice is going to be in every major supermarket in the country, and they're going to be leading that charge. And yet the stock went down on unbelievable earnings. and so that we can't control but we're super proud of what they've done. They've done exactly what we expected them to do. What we didn't expect was that, you know, people don't care right now.

31:32 But that, you know, we don't think that that'll persist forever. So, again, we really love what our companies are doing. They've, you know, they've all have been moving things forward very well. Even, again, another company we don't have a huge equity position in Like HeartBean, this thing is what appears to be super close to being approved for heart attack detection. It could save millions of lives. It could be everywhere. Yet, the market is just worried about financing risk and is just worried that maybe they won't get there. And, you know, we've seen this before. And we've seen it where, you know, it gets dark like this. I mean, today, I mean, I couldn't, you know... I couldn't tell you that, like right now, it seems like people are throwing in the towels on these things. And, you know, maybe it goes lower.

32:23 I don't know. But I certainly don't think that, you know, these great companies are just going to be totally ignored forever. So, you know, the markets have been confounding for us and what have you. But again, I can't control the markets. And we're very hopeful that we're near the bottom. And I think on execution, you know, these business development partnerships are super important. You know, I'm working most of my time right now in making sure we find the right partner for public ventures that we, you know, and Javier and team are doing a great job at PatentVest. They're at a, you know, legal tech conference right now. They're talking to a number of companies that are interested in partnering with PatentVest, as well as attorneys that want to join the bench.

33:12 and companies that are looking for a unique solution to prosecute IP. So, you know, a lot of execution needs to be done there and it's, you know, and I know the team is working very hard after having built a great platform. Also in, with exercise, we've got to get some deals done with marketing partners to sell these compounds that we're going to be putting into production shortly. And I think with Pollux, execution on the clinical trial and then ultimately probably partnerships with Vic Pharma that are going to want to bring that to the global medical landscape. With that, we have been in the business of turning ideas and what we think are valuable assets into enterprises.

34:04 None of that has changed. We've got four very valuable enterprises in our mind and we're excited to get these things commercialization. It's not going to be easy. It's very tough. We are buckling down. We are scratching to get these things lifted and we think close on several of them. So we remain optimistic, albeit sanguine about the current environment that we're in. So with that, George, I'll turn it over to you to to take

34:45 some questions. Yeah, you can, Chris, you might want to pull them up as well. I want to make a comment that we are in the middle of financing with Exazyme under an S-1 that's been filed. I would have you take a look at that S-1. There's a lot of information in there. If you haven't had a chance to look at the presentation that Managers has made here, there is a recording from NetRoadShow that I think we're going to try to put out to all of our shareholders and account holders tomorrow and you have an opportunity. A lot of the questions I have in the chat board are regarding Exazyme and that presentation. I just want to make sure that we're under this S-1 and this financing right now so we really can't do much as far as going over and above what's instated in the S-1.

35:31 But that said, Chris, one of the questions is on cannabinoids. Can you talk a little bit about That market and what you see as far as what Exazyme could do in the cannabinoid market?

35:47 Yeah, cannabinoids are super interesting. We'll see, I think, both at a federal level and state level it's been constrained because cannabinoid development has been, I wouldn't say a dirty word, it's just been, I think, muddled. And It's been held back from a nutritional supplement perspective, but from a pharmaceutical perspective, I think it was constrained as well, but I think it's starting to gain a lot of appeal because you've got the CB1 and CB2 receptors that are on so many of your cells in your body, and these compounds have been shown to do lots of things, whether it's deal with all kinds of medical conditions and I think the company has demonstrated that they have the only syn-bio platform that can actually manufacture these as drugs or as nutritional supplements and so we're pretty excited about it because there's so much scientific research that's already been done on cannabinoids but a lot of them just couldn't be made and we can so we're hoping that we can spin out a new company out of at some point to serve that market because we see it as a multi-billion dollar market.

37:08 There's one cannabinoid that's been approved that is doing over a billion in sales and got bought for about $7 billion. We think we can create multiples of those potentially. It's a super exciting platform potential amongst a lot of the other things that are being developed at ExoZymes.

37:32 So the question about the AI drug designing and the whole frontier of new drugs that AI is discovering. Where does Exozyme fit in with these AI companies on that?

37:46 The great thing about these tools companies, whether it was PatVest or now Exozymes or even what we're doing at MDB, we have processes that when we would look at a company, to give you an example now, We would look at a new co. We would get into a data room of a company looking for financing, and it would take us months to complete diligence to see if we wanted to get behind it. In some cases, we're able to rule in and rule out in a day. It's shocking that we've been able to do that. Well, it's the same in exozymes right now. So what happened was exozymes has a toolkit of these enzymes. They understand how to manufacture enzymes, and they understand these pathways to of how to make a drug using enzymes or make a compound using enzymes.

38:34 AI just supercharged it because they were able to now utilize much more data that they have to get to an answer quicker. So their ability to effectively prototype a new drug has gone from, in the old synthetic biology, taking years to do, they can do it in sometimes days. That's how powerful this is. It's going to have a massively profound impact on new drugs and treating disease that goes well beyond exosomes. But exosomes has a toolkit with known compounds and known pathways to be able to get there so fast. And that's what's exciting. And I think that now that we've shown the ability to scale manufacturing, Drug companies have to be interested in this.

39:29 We've got to get out, and that's why I said we've got to get partnerships done with drug companies because we have it now. We have the ability to make compounds that they need to fill their pipeline with that you can't just go get from other people. We have a unique capability of exercise that no other symbiote company has. Super exciting time. We're going to hit on one of these drugs That's going to really open the sky for the company, I think. It's a very, very exciting time for exozymes.

40:04 From the pharmaceutical perspective, how long does it take to gin up some interest, whether the cannabinoids or a new molecule? For those that don't understand that pharmaceutical pathway, what would that look like?

40:17 We have the ability to manufacture small quantities quickly so they can be tested very quickly in animals. Again, many of these compounds are not easy to make. Even the drug that Pollux is putting in the clinic, it's a small molecule, but it wasn't trivial to manufacture that drug. It actually took time to get clean manufacturing for that drug. We're going to be able to dramatically enhance that and get these things to the clinic quickly so we can test them pre-clinically, which then gives Big Pharma... you know, the confidence to put it into the clinic with humans, you know, quickly. So, I think the cycle can be much faster. And we've seen some of these AI, let's call it drug discovery platforms, doing big deals with folks like Antropic and others, and we think that that's totally possible for exozymes as well.

41:14 So, question on the large position, we have large position in all four of these, smaller in Buddha and smaller in in HeartBeam, but large in those four. Can you kind of describe what your thinking is on the distribution strategy, if you just get to an inflection point, what you mean by that?

41:38 Well, I think that, you know, I'm hoping that Exxon gets to an inflection point in 2027 so that we, it's already public, it would be very easy to distribute. We would, you know, at Once it gets to that inflection point, they've got their financing, you know, done per se, then that's a good time to distribute. So hopefully that's, we're hoping that that all happens and we can make that distribution of those shares to the shareholders, you know, very soon. So that's an easy one. The other ones are not public yet. So the idea of getting them public is, you know, is important to us. And we have We are talking about a way to get public ventures public in a partnership and we're looking at that.

42:26 We're also looking at patent vets and potentially taking that public as well. If we do, then it's easy to distribute those assets. Our first priority being that we're in the public venture business to get these companies public. and so that's the easiest way.

42:50 Do you worry that if you do that early it would put pressure on the stock? Is that why you'd look at them, you'd want them to be healthy, trading volume, well financed?

43:00 Yeah, exercise is not trading much volume. It hasn't gotten that real pop yet based on commercialization or a depression point, but when it does we've had in the history when these things really hit, they They trade millions of shares a day, so distributing out millions of shares is not going to negatively impact it.

43:21 Paul X questions. So, you know, Paul X is going into, as you said, into people here later this year. Where is the confidence as far as that this drug on the data we have so far has a better probability of working in, say, a cancer drug? Do you have any kind of a feel for that? Why you're confident that this might have a higher probability of actually showing some success in people?

43:51 Well, listen, it's been validated this pathway, you know, basically enables takes and breaks off producing beta cells. And it's been shown with human cells, you know, in animals. But, and that's a big thing. I mean, that's never been done with a drug ever, you know, and So, safely, that is. It was done with a drug unsafely, and it got pulled off the market. Or got pulled out of trials, I should say. But, yeah, if we can do it safely, then that's totally great. I mean, I don't know if, you know, it doesn't get any bigger than that in my mind.

44:37 You know, GOP ones are big, but this will be, to me, a whole new category that we could be the leader in. So, and we're super close to knowing you. We're very close to knowing if it's safe and we're also pretty darn close to knowing whether it grows beta cells too. So it's an exciting time. It's sort of like it's exciting and it's a great time. I mean it If it works, it's going to be transformative.

45:17 So that's pretty much, we covered generally the questions here. I'm going to go ahead and put it back to you and go ahead and close out, Chris.

45:25 You recovered all the questions already? Yep.

45:29 All right. I don't understand the last question, so I'm going to go ahead and pass on it.

45:41 Okay. All right, guys. Well, we're working our tails off to get these companies to an inflection point, get them to be super valuable companies, as we've done with a lot of our companies in the past. We're excited. We're also stressed as well. I mean, the market's not been kind to these companies and to us. But Thank you so much for having me. Nothing good is easy, and we're still just as excited about all these companies and the mission that we undertook when we went public. So thanks again.

46:55 Thank you, everybody. This concludes today's webinar.

Follow MDB Capital Holdings, LLC into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

George Brandon

President and Head of Community Development, MDB Capital Holdings

Chris Marlett

Chief Executive Officer and Co-Founder, MDB Capital Holdings

More from MDB Capital Holdings, LLC